Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) - Pipeline Insight, 2018

  • ID: 4037514
  • Drug Pipelines
  • 50 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • AnGes MG Inc
  • Athersys Inc
  • BiogenCell Ltd
  • ID Pharma Co Ltd
  • miRagen Therapeutics Inc
  • Proteon Therapeutics Inc
  • MORE
'Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
The report assesses the active Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology:

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report:
  • The report provides a snapshot of the pipeline development for the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
  • The report also covers the dormant and discontinued pipeline projects related to the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
Reasons to Purchase:
  • Establish comprehensive understanding of the pipeline activity across this Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress
Note: Please allow up to 48 hours for delivery of this report after payment has been made.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AnGes MG Inc
  • Athersys Inc
  • BiogenCell Ltd
  • ID Pharma Co Ltd
  • miRagen Therapeutics Inc
  • Proteon Therapeutics Inc
  • MORE
1. Report Introduction

2. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Overview

3. Pipeline Therapeutics
  • An Overview of Pipeline Products for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
4. Comparative Analysis

5. Products in Clinical Stage
5.1 Drug Name : Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name : Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
7. Therapeutic Assessment
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name : Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Appendix
Report Methodology
Consulting Services
Disclaimer

List of Tables:
Table 1: Total Products for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
Table 2: Products in Clinical Stage
Table 3: Products in Non-clinical Stage
Table 4: Assessment by Route of Administration
Table 5: Assessment by Stage and Route of Administration
Table 6: Assessment by Molecule Type
Table 7: Assessment by Stage and Molecule Type
Table 8: Inactive Products

List of Figures:
Figure 1: Total Products for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
Figure 2: Products in Clinical Stage
Figure 3: Products in Non-clinical Stage
Figure 4: Assessment by Route of Administration
Figure 5: Assessment by Stage and Route of Administration
Figure 6: Assessment by Molecule Type
Figure 7: Assessment by Stage and Molecule Type
Figure 8: Inactive Products
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AnGes MG Inc
  • AstraZeneca Plc
  • Athera Biotechnologies AB
  • Athersys Inc
  • Bayer AG
  • Betagenon AB
  • BiogenCell Ltd
  • CardioVascular BioTherapeutics Inc
  • Celgene Corp
  • Diffusion Pharmaceuticals Inc
  • Foresee Pharmaceuticals LLC
  • Hemostemix Ltd
  • ID Pharma Co Ltd
  • Juventas Therapeutics Inc
  • LipimetiX Development Inc
  • miRagen Therapeutics Inc
  • Novartis AG
  • Nuo Therapeutics Inc
  • Proteon Therapeutics Inc
  • Recardio GmbH
  • Resverlogix Corp
  • Sigma-Tau SpA
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll